A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
Latest Information Update: 06 Nov 2024
At a glance
- Drugs Golcadomide (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
Most Recent Events
- 04 Nov 2024 Status changed from not yet recruiting to recruiting.
- 06 Aug 2024 New trial record